Incidence, treatment, and outcomes of isoniazid mono-resistant Mycobacterium tuberculosis infections in Alberta, Canada from 2007-2017

PloS One
Brett D EdwardsDina Fisher

Abstract

Isoniazid resistant Mycobacterium tuberculosis (Hr-TB) is the most frequently encountered TB resistance phenotype in North America but limited data exist on the effectiveness of current therapeutic regimens. Ineffective treatment of Hr-TB increases patient relapse and anti-mycobacterial resistance, specifically MDR-TB. We undertook a multi-centre, retrospective review of culture-positive Hr-TB patients in Alberta, Canada (2007-2017). We assessed incidence and treatment outcomes, with a focus on fluoroquinolone (FQ)-containing regimens, to understand the risk of unsuccessful outcomes. Rates of Hr-TB were determined using the mid-year provincial population and odds of unsuccessful treatment was calculated using a Fisher's Exact test. One hundred eight patients of median age 37 years (IQR: 26-50) were identified with Hr-TB (6.3%), 98 of whom were able to be analyzed. Seven percent reported prior treatment. Rate of foreign birth was high (95%), but continent of origin did not predict Hr-TB (p = 0.47). Mean compliance was 95% with no difference between FQ and non-FQ regimens (p = 1.00). Treatment success was high (91.8%). FQ-containing regimens were frequently initiated (70%), with no difference in unsuccessful outcomes compared to ...Continue Reading

References

Nov 13, 2007·Journal of Gastroenterology and Hepatology·Alma TostmannRichard Dekhuijzen
Dec 18, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Adithya CattamanchiPayam Nahid
Mar 30, 2010·The Journal of Infection·Didi BangVibeke Østergaard Thomsen
Jan 1, 2010·Tuberculosis Research and Treatment·Justin T Denholm, Emma S McBryde
Jun 8, 2013·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·C-C ShuL-N Lee
Jul 6, 2014·QJM : Monthly Journal of the Association of Physicians·M L MunangM Dedicoat
Feb 1, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J-Y ChienC-J Yu
Nov 4, 2015·Antimicrobial Agents and Chemotherapy·Hyun LeeWon-Jung Koh
Apr 3, 2016·The Lancet Infectious Diseases·Robert S WallisAlimuddin Zumla
Aug 10, 2016·Cold Spring Harbor Perspectives in Medicine·Michael J TrimbleRobert E W Hancock
Mar 2, 2018·Annals of the American Thoracic Society·Max O'Donnell
Mar 30, 2018·The Lancet. Respiratory Medicine·Federica FregoneseDick Menzies
May 29, 2018·Tuberculosis Research and Treatment·C PadmapriyadarsiniPrathap Tharyan
Dec 5, 2018·PloS One·Jose Gabriel Cornejo GarciaDavid A J Moore
Aug 3, 2019·The European Respiratory Journal·Helen R StaggUNKNOWN London INH-R TB study group
Sep 14, 2019·Journal of the American College of Cardiology·Mahyar EtminanJames M Brophy
Oct 12, 2019·The European Respiratory Journal·Roland Diel, Neil W Schluger
Nov 16, 2019·American Journal of Respiratory and Critical Care Medicine·Payam NahidBarbara Seaworth

❮ Previous
Next ❯

Citations

Nov 20, 2020·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·M A Abo-KadoumJianping Xie

❮ Previous
Next ❯

Software Mentioned

iPHIS

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.